Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

167 Clinical Updates found
(Left to right) Sascha Roth, Luis Diaz, Imtiaz Hussain, Andrea Cercek, Avery Holmes, and Nisha Varughese.
Top Cancer Treatment Advances at MSK in 2022
Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in many types of cancer treatment for patients in 2022. Here are some of the most important developments.
Charlotte Ariyan
A Promising Neoadjuvant Combination Immunotherapy for Advanced Melanoma
Neoadjuvant relatlimab and nivolumab achieved high response rates with a favorable safety profile in patients with advanced melanoma, according to initial data from a small clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK) and the University of Texas MD Anderson Cancer Center (MD Anderson).
Martin R. Weiser, MD
Updated Clinical Calculator Guides Treatment Plan for Rectal Cancer
Physicians at Memorial Sloan Kettering Cancer Center (MSK) have developed and validated clinical calculators to help patients estimate their likelihood of avoiding a recurrence after treatment for colorectal cancer.
Dr. Motzer reviewing radiology images with nurse.
MSK Research Roundup at ESMO Congress 2022: Practice-Changing Advances in Bladder Cancer, Endometrial Cancer, Renal Cell Carcinoma, Colorectal Cancer, and Breast Cancer
Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough findings for new treatment approaches in several cancer indications at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9 to 13 in Paris. Highlights included clinically meaningful benefits for new treatment strategies in advanced bladder cancer, endometrial cancer, and renal cell carcinoma. Additionally, MSK experts shared their perspectives on previously reported groundbreaking trials of new treatment approaches in colorectal cancer and HER2-low metastatic breast cancer.
Learn About the Benefits of Referring Your Patients with Urologic Cancers to MSK
Learn About the Benefits of Referring Your Patients with Urologic Cancers to MSK
Memorial Sloan Kettering Cancer Center’s urology service is comprised of a multidisciplinary team of experts that is among the most experienced in the field. Patients referred to MSK will have access to life-saving clinical trials, pioneering research, and the latest therapies and surgical advances that are tailored specifically for them. Hear from MSK surgeon Bernard Bochner as he talks about achieving the best coordinated care possible for patients.
Image of a lung
MSK Clinical Research Roundup
The MSK Clinical Research Roundup keeps physicians up to date on the latest and most noteworthy patient treatments, clinical trials, and translational research happening at MSK.
David Jones, MD performing image guided surgery
A Genomic Model To Predict Recurrence of Early-Stage Lung Adenocarcinoma
Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.
Vivian Strong, MD in the operating room
For Patients With CDH1 Mutations, Total Gastrectomy Can Reduce Stomach Cancer Mortality Rate
Signet ring cell cancer (SRCC) was detected in the vast majority of patients with CDH1 mutations following total gastrectomy.
Urologic surgeon speaking with patient
Patients with Bladder Cancer Report Favorable Long-Term Quality of Life After Radical Cystectomy
A large cohort of patients with high-risk bladder cancer who underwent radical cystectomy and urinary tract reconstruction at Memorial Sloan Kettering Cancer Center reported favorable recovery and health-related quality of life within 24 months across most outcome measures.
HiSeq 2500 Ultra-High-Throughput Sequencing System powers MSK-IMPACT
Sequencing Cerebrospinal Fluid Is Clinically Useful in Pediatric, Adolescent, and Young Adult Brain Tumors
Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with brain tumors.